JAK and TYK-2 inhibitors and indications in SpA: ● Tofacitinib ➣ Pan JAKi (AS, PsA) ● Baricitinib ➣ JAK1,2 ● Upadacitinib ➣ JAK1 (AxSpA, PsA) ● Deucravacitinib ➣ TYK2 (PsA) Carol Langford, Year in Review #ACR22 @RheumNow https://t.co/EMLEvptySS

Differences between #uveitis pattern in AS vs. PsA and IBD 👇 This is always asked to our rheum fellows during Kelley's hour 🤓 #ACR22 @RheumNow @rheumarhyme @trishiemd @RheumaRamblings @RheumaRambolMD https://t.co/gWxQ9xdb06

Jorge et al. @AprilJorgeMD Incidence SLE nephritis - 16% onset, 35% 15 years. 44.7% men vs 28.6% women at 10 years. 40% Black, 38% Hispanic, 40% Asian, 23% White. @RheumNow #ACR22 Abstr#0538 https://t.co/Nbx16jZAN7 https://t.co/BEnAtbcIHt

GPA pts can have dacryoadenitis (ddx 👇) where pt's lateral eye/s can be curved due to swelling. How to examine? Use thumb to retract eyelid & reveal lacrimal gland underneath, ask pt to look medially #ACR22 @RheumNow @rheumarhyme @doktora_ging @PhRheumaJr #RheumTwitter https://t.co/pJYMffhYWx

Deucravacitinib (TYK2 inihibitor) already studied in PsO and PsA, has show efficacy in a phase 2 trial for treatment of SLE. Improvement in SRI(4), BICLA, LLADS, CLASI-50 and joint count Abs#1117 @RheumNow #ACR22 https://t.co/XElIuMmud9

🦋Only 15% of pts with localized DLE develop SLE Risk factors for conversion: 🔸ANA+ at BL 🔸dsDNA+ 🔸Gen'd DLE 🔸Cytopenia 🔸Photosensitivity 🔸abn. UA #ACR22 @RheumNow @rheumarhyme https://t.co/n7cKjC1oaR

Tofighi et al. VTE in SLE nephritis. 10% VTE, 5.2% VTE after SLE nephritis diagnosis. Risks - Black patients, ds-DNA+, SDI, aPL+, SLEDAI. @RheumNow #ACR22 Abstr#0541 https://t.co/G6q0qvirf7 https://t.co/B8STBTMy14

Prelude to a Meeting #ACR22 https://t.co/ESjDnNue1H https://t.co/EHt5tgFOn3

ACR Best Abstracts - Day 1 The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest). https://t.co/ndSBqYszlo https://t.co/vOHtLTFux6

Across 9 trials of Upadacitinib in RA, PsA and AS, 40%–50% of patients had ≥ 2 CV risk factors, ≥ 65 years 6%–23%. Rates of adjudicated MACE and VTE with UPA were infrequent, consistent with background rates in RA, PsA, and AS Abst 0510 https://t.co/HDkQ6ELnAy #ACR22 @RheumNow https://t.co/SRJYdFFNIQ

New concept of sJIA to MAS as a continuum on the spectrum of disease severity. Molecular basis via impact of mTORC1 (mechanistic target of rapamycin complex 1) inhibition in Il1rn-/- mice. Looking forward to the full paper. Huang Z Abs004 https://t.co/3OtIp90PnG #ACR22 @RheumNow https://t.co/PPHQj8bYKu

How can we differentiate statin-assoc autoimmune necrotizing myopathy from toxic statin #myopathy?🔎 Remember this important slide👇 #ACR22 @Rheumnow #acrreview https://t.co/hKMJuGDJWt